Skip to main content

Advertisement

Table 1 Clinicopathologic characteristics of patients with HER2-negative breast cancer included for analysis

From: Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

Characteristics Cohort 1: SEER Cohort 2: FDUSCC Cohort 3: Publicly available cases Cohort 4: Publicly available NCT cases
  N = 67,932 % N = 2,338 % N = 837 % N = 483 %
Age, years (IQR) 61 (51–70)   53 (45–60)   55 (45–65)   50 (42–58)  
Tumor size         
 T0–1 42,281 62.2 1,132 48.4 155 38.8 33 6.8
 T2 20,253 29.8 1,004 42.9 210 52.6 244 50.5
 T3–4 5,398 7.9 202 8.6 34 8.5 206 42.7
Lymph nodes         
 Negative 47,078 69.3 1,168 50.2 285 47.3 150 31.1
 Positive 20,854 30.7 1,161 49.8 317 52.7 333 68.9
Grade         
 I 17,172 26.2 39 1.7 102 13.2 31 6.8
 II 29,359 44.7 1,610 68.9 244 31.6 173 38.1
 III and UD 19,129 29.1 689 29.5 426 55.2 250 55.1
Subgroup         
 ER+/PgR+ 50,679 74.6 1,686 72.1 391 46.7 216 44.7
 ER+/PgR– 7,075 10.4 177 7.6 130 15.5 72 14.9
 ER–/PgR+ 561 0.8 34 1.5 36 4.3 17 3.5
 ER–/PgR– 9,617 14.2 441 18.9 280 33.5 178 36.9
Median follow-up, months (IQR) 11 (5–17)   37 (25–50)   49 (20–72)   36 (21–49)  
  1. FDUSCC Fudan University Shanghai Cancer Center, IQR Interquartile range, NCT Neoadjuvant chemotherapy, SEER Surveillance, Epidemiology and End Results program, UD Undifferentiated